First Time Loading...

Incyte Corp
NASDAQ:INCY

Watchlist Manager
Incyte Corp Logo
Incyte Corp
NASDAQ:INCY
Watchlist
Price: 52.35 USD -0.89% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. [ Read More ]

The intrinsic value of one INCY stock under the Base Case scenario is 76.61 USD. Compared to the current market price of 52.35 USD, Incyte Corp is Undervalued by 32%.

Key Points:
INCY Intrinsic Value
Base Case
76.61 USD
Undervaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Incyte Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling INCY stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Incyte Corp

Provide an overview of the primary business activities
of Incyte Corp.

What unique competitive advantages
does Incyte Corp hold over its rivals?

What risks and challenges
does Incyte Corp face in the near future?

Has there been any significant insider trading activity
in Incyte Corp recently?

Summarize the latest earnings call
of Incyte Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Incyte Corp.

Provide P/S
for Incyte Corp.

Provide P/E
for Incyte Corp.

Provide P/OCF
for Incyte Corp.

Provide P/FCFE
for Incyte Corp.

Provide P/B
for Incyte Corp.

Provide EV/S
for Incyte Corp.

Provide EV/GP
for Incyte Corp.

Provide EV/EBITDA
for Incyte Corp.

Provide EV/EBIT
for Incyte Corp.

Provide EV/OCF
for Incyte Corp.

Provide EV/FCFF
for Incyte Corp.

Provide EV/IC
for Incyte Corp.

Show me price targets
for Incyte Corp made by professional analysts.

What are the Revenue projections
for Incyte Corp?

How accurate were the past Revenue estimates
for Incyte Corp?

What are the Net Income projections
for Incyte Corp?

How accurate were the past Net Income estimates
for Incyte Corp?

What are the EPS projections
for Incyte Corp?

How accurate were the past EPS estimates
for Incyte Corp?

What are the EBIT projections
for Incyte Corp?

How accurate were the past EBIT estimates
for Incyte Corp?

Compare the revenue forecasts
for Incyte Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Incyte Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Incyte Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Incyte Corp compared to its peers.

Compare the P/E ratios
of Incyte Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Incyte Corp with its peers.

Analyze the financial leverage
of Incyte Corp compared to its main competitors.

Show all profitability ratios
for Incyte Corp.

Provide ROE
for Incyte Corp.

Provide ROA
for Incyte Corp.

Provide ROIC
for Incyte Corp.

Provide ROCE
for Incyte Corp.

Provide Gross Margin
for Incyte Corp.

Provide Operating Margin
for Incyte Corp.

Provide Net Margin
for Incyte Corp.

Provide FCF Margin
for Incyte Corp.

Show all solvency ratios
for Incyte Corp.

Provide D/E Ratio
for Incyte Corp.

Provide D/A Ratio
for Incyte Corp.

Provide Interest Coverage Ratio
for Incyte Corp.

Provide Altman Z-Score Ratio
for Incyte Corp.

Provide Quick Ratio
for Incyte Corp.

Provide Current Ratio
for Incyte Corp.

Provide Cash Ratio
for Incyte Corp.

What is the historical Revenue growth
over the last 5 years for Incyte Corp?

What is the historical Net Income growth
over the last 5 years for Incyte Corp?

What is the current Free Cash Flow
of Incyte Corp?

Financials

Balance Sheet Decomposition
Incyte Corp

Current Assets 4.6B
Cash & Short-Term Investments 4.1B
Receivables 743.6m
Other Current Assets -196.9m
Non-Current Assets 2.1B
Long-Term Investments 187.7m
PP&E 777m
Intangibles 279.1m
Other Non-Current Assets 892.8m
Current Liabilities 1.2B
Accounts Payable 1.5B
Accrued Liabilities 735.7m
Other Current Liabilities -952.6m
Non-Current Liabilities 351.9m
Long-Term Debt 29.2m
Other Non-Current Liabilities 322.7m
Efficiency

Earnings Waterfall
Incyte Corp

Revenue
3.7B USD
Cost of Revenue
-232.5m USD
Gross Profit
3.5B USD
Operating Expenses
-2.8B USD
Operating Income
651.8m USD
Other Expenses
-54.2m USD
Net Income
597.6m USD

Free Cash Flow Analysis
Incyte Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

INCY Profitability Score
Profitability Due Diligence

Incyte Corp's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Exceptional ROIC
64/100
Profitability
Score

Incyte Corp's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

INCY Solvency Score
Solvency Due Diligence

Incyte Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Negative Net Debt
Low D/E
87/100
Solvency
Score

Incyte Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

INCY Price Targets Summary
Incyte Corp

Wall Street analysts forecast INCY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INCY is 76.86 USD with a low forecast of 61.61 USD and a high forecast of 96.6 USD.

Lowest
Price Target
61.61 USD
18% Upside
Average
Price Target
76.86 USD
47% Upside
Highest
Price Target
96.6 USD
85% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

INCY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

INCY Price
Incyte Corp

1M 1M
-10%
6M 6M
-5%
1Y 1Y
-29%
3Y 3Y
-38%
5Y 5Y
-29%
10Y 10Y
+10%
Annual Price Range
52.35
52w Low
52.16
52w High
75.34
Price Metrics
Average Annual Return 2.59%
Standard Deviation of Annual Returns 13.14%
Max Drawdown -52%
Shares Statistics
Market Capitalization 11.7B USD
Shares Outstanding 226 125 000
Percentage of Shares Shorted 4.3%

INCY Return Decomposition
Main factors of price return

What is price return decomposition?

INCY News

Other Videos

Last Important Events
Incyte Corp

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Incyte Corp

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Incyte Corp Logo
Incyte Corp

Country

United States of America

Industry

Biotechnology

Market Cap

11.7B USD

Dividend Yield

0%

Description

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,094 full-time employees. The firm also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. The company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.

Contact

DELAWARE
Wilmington
1801 Augustine Cut off
+13024986700.0
https://www.incyte.com/

IPO

1993-12-06

Employees

2 094

Officers

CEO & Chairman
Mr. Herve Hoppenot
Executive VP & CFO
Ms. Christiana Stamoulis MBA
Executive VP & GM of North America
Dr. Barry P. Flannelly M.B.A., Pharm.D.
Executive VP & Chief Medical Officer
Dr. Steven H. Stein M.D.
President and Head of Research & Development
Dr. Pablo J. Cagnoni M.D., Ph.D.
VP of Finance, Chief Accounting Officer & Controller
Mr. Thomas Tray
Show More
Executive VP & Head of Global Technical Operations
Mr. Michael James Morrissey
Executive VP, General Counsel & Corporate Secretary
Sheila A. Denton
Vice President of Investor Relations & Corporate Communications
Ms. Pamela M. Murphy
Executive Vice President of Human Resources
Ms. Paula J. Swain
Show Less

See Also

Discover More
What is the Intrinsic Value of one INCY stock?

The intrinsic value of one INCY stock under the Base Case scenario is 76.61 USD.

Is INCY stock undervalued or overvalued?

Compared to the current market price of 52.35 USD, Incyte Corp is Undervalued by 32%.